Q-omics provides the consensus-scored FBXW5 profile across patient tissues and cancer cell-line models. FBXW5 expression is associated with patient survival in 30 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FBXW5 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, FBXW5 RNA expression shows 17,781 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where FBXW5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXW5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXW5 survival associations across molecular data types. FBXW5 RNA expression shows survival associations in the most cancer types (30), followed by mutation status (8) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXW5 RNA expression–survival associations across cancer types. High FBXW5 expression shows unfavorable associations in ACC, UVM, LGG and UCS, but favorable associations in UCEC and DLBC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FBXW5 RNA expression.
This table summarizes FBXW5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FBXW5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXW5 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, LUAD, CHOL and LUSC. The KIRC box plot shows higher FBXW5 RNA expression in tumor versus normal tissue (log2 FC = +0.573, t-test p < 0.001).
This table shows molecular features associated with FBXW5 in patient tissues and cancer cell lines. In patient samples, FBXW5 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXW5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
